compound introduction
IgG4抗体将主导血吸虫病、淋巴丝虫病和过敏原免疫治疗后患者的IgG反应。与其他IgG亚类不同，IgG4不激活补体。IgA-IgG4联合缺乏与复发性化脓性感染有关。 由骨髓瘤血浆制备，经美国食品药品监督管理局要求的测试显示，骨髓瘤血浆对HBsAg、抗HCV、抗HBc无反应，对抗HIV 1和2呈阴性 IgG4 antibodies will dominate the IgG response in schistosomiasis, lymphatic filariasis, and in patients after allergen immunotherapy. Unlike the other IgG subclasses, IgG4 does not activate complement. A combined IgA-IgG4 deficiency has been associated with recurrent pyogenic infections. Prepared from myeloma plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA-required tests
